Chiesi Gains U.S. Rights to Protalix' Phase III Fabry Disease Candidate PRX-102

Protalix BioTherapeutics said today it has granted Chiesi Farmaceutici exclusive U.S. rights to develop and commercialize the Phase III Fabry disease treatment PRX-102 (pegunigalsidase alfa), in an expansion of the companies’ partnership that could yield for Protalix an additional up to $805 million, plus royalties.The extra money will raise to a total $95 million in upfront payments and development costs, plus $1 billion in milestones, what Chiesi could potentially spend under its agreeme